alexa Risk of Thromboembolism in Patients with Immune Thrombocytopenia

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Global Summit on Oncology and Cancer Therapy

New York, USA
Risk of Thromboembolism in Patients with Immune Thrombocytopenia

Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmune-mediated platelet destruction and impairment of platelet production [1,2]. Autoimmune-mediated accelerated platelet destruction with subsequent clearance in the reticuloendothelial (RE) system can be reduced by RE phagocytosis-preventing agents, such as intravenous immunoglobulin (IVIG), intravenous anti-D, or corticosteroids, or may be permanently resolved by splenectomy.

 

 

Citation: Takagi S, Suzuki I, Watanabe S (2015) Risk of Thromboembolism in Patients with Immune Thrombocytopenia. J Hematol Thrombo Dis 3:185. doi: 10.4172/2329-8790.1000185

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top